Trade Agreement: Canadian Free Trade Agreement (CFTA)
Tendering Procedures: Generally only one firm has been invited to bid
Non-Competitive Procurement Strategy: Exclusive Rights
Comprehensive Land Claim Agreement: No
Vendor Name and Address:
GlaxoSmithKline Inc.
7333 Mississauga Road North
Mississauga Ontario
Canada
L5N6L4
Nature of Requirements:
1. Definition of the requirement
Canada has a requirement for the supply of a firm quantity of 509,688 doses, and optional quantity of up to a maximum of 1,026,528 doses of Infanrix-hexa vaccine.
2. Criteria for assessment of the Statement of Capabilities (Minimum Essential Requirements)
Any interested supplier must demonstrate by way of a statement of capabilities that its vaccine meets the following requirements:
a. Vaccine offered must be approved by Health Canada and provide protection against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilis influenzae type b disease in infants and children 6 weeks to 2 years.
b. Provide Drug Identification Number (DIN)
c. must be able to deliver vaccine to various locations across Canada
3. Applicability of the trade agreement(s) to the procurement
This procurement is subject to the Canadian Free Trade Agreement.
4. Justification for the Pre-Identified Supplier
This requirement is being negotiated with GlaxoSmithKline Inc. as they are the only known supplier capable of providing vaccine approved by Health Canada’s Biologics and Genetic Therapies Directorate for protection against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilis influenzae type b disease in infants and children 6 weeks to 2 years.
The following exception(s) to the Government Contracts Regulations is (are) invoked for this procurement under subsection 6(d) - only one person is capable of performing the work;
6. Period of the proposed contract and delivery date
The contract period of is April 1 2019 to March 31, 2020 with option to extend for an additional two (2) one year periods. Delivery is as-and-when required.
7. Name and address of the pre-identified supplier
GlaxoSmithKline Inc
7333 Mississauga Rd
Mississauga Ontario
L5N 6L4
8. The closing date and time for accepting statements of capabilities is December 20, 2018
9. Inquiries and statements of capabilities are to be directed to:
Sharon Joy
Supply Specialist
S••••••••@••••••••.••.ca
Delivery Date: 04/12/2018
You are hereby notified that the government intends to negotiate with one firm only as identified above. Should you have any questions concerning this requirement, contact the contracting officer identified above.
An Advance Contract Award Notice (ACAN) allows departments and agencies to post a notice, for no less than fifteen (15) calendar days, indicating to the supplier community that it intends to award a good, service or construction contract to a pre-identified contractor. If no other supplier submits, on or before the closing date, a Statement of Capabilities that meets the requirements set out in the ACAN, the contracting authority may then proceed with the award. However, should a Statement of Capabilities be found to meet the requirements set out in the ACAN, then the contracting authority will proceed to a full tendering process.
Suppliers who consider themselves fully qualified and available to provide the services/goods described herein, may submit a statement of capabilities in writing to the contact person identified in this Notice on or before the closing date of this Notice. The statement of capabilities must clearly demonstrate how the supplier meets the advertised requirements.
The PWGSC file number, the contracting officer's name and the closing date of the ACAN must appear on the outside of the envelope in block letters or, in the case of a facsimile transmission, on the covering page.
The Crown retains the right to negotiate with suppliers on any procurement.
Documents may be submitted in either official language of Canada.
